{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:08:26Z","timestamp":1794330506424,"version":"4.9.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T00:00:00Z","timestamp":1539561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000027","name":"Institute of Cancer Research","doi-asserted-by":"publisher","award":["MOP-142233"],"award-info":[{"award-number":["MOP-142233"]}],"id":[{"id":"10.13039\/501100000027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Phys"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40658-018-0224-9","type":"journal-article","created":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T08:25:02Z","timestamp":1534235102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT"],"prefix":"10.1186","volume":"5","author":[{"given":"Michela","family":"Del Prete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Arsenault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Saighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Alexandre","family":"Buteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Celler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2123-145X","authenticated-orcid":false,"given":"Jean-Mathieu","family":"Beauregard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,15]]},"reference":[{"key":"224_CR1","doi-asserted-by":"publisher","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124\u201330. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.15.2553\n                    \n                  .","DOI":"10.1200\/JCO.2007.15.2553"},{"issue":"2","key":"224_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1607427\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"224_CR3","doi-asserted-by":"crossref","unstructured":"Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTA0Tyr3] octreotate: comparison with [111In-DTPA0] octreotide in patients. Eur J Nucl Med. 2001;28(9):1319\u201325.","DOI":"10.1007\/s002590100574"},{"issue":"9","key":"224_CR4","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1007\/s00259-017-3678-4","volume":"44","author":"A Sundlov","year":"2017","unstructured":"Sundlov A, Sjogreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, et al. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44(9):1480\u20139. \n                    https:\/\/doi.org\/10.1007\/s00259-017-3678-4\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"224_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2967\/jnumed.112.107524","volume":"54","author":"M Sandstrom","year":"2013","unstructured":"Sandstrom M, Garske-Roman U, Granberg D, Johansson S, Widstrom C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54(1):33\u201341. \n                    https:\/\/doi.org\/10.2967\/jnumed.112.107524\n                    \n                  .","journal-title":"J Nucl Med"},{"issue":"9","key":"224_CR6","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1007\/s00259-017-3688-2","volume":"44","author":"M Del Prete","year":"2017","unstructured":"Del Prete M, Buteau FA, Beauregard JM. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging. 2017;44(9):1490\u2013500. \n                    https:\/\/doi.org\/10.1007\/s00259-017-3688-2\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"224_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1102\/1470-7330.2011.0012","volume":"11","author":"JM Beauregard","year":"2011","unstructured":"Beauregard JM, Hofman MS, Pereira JM, Eu P, Hicks RJ. Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT\/CT system. Cancer Imaging. 2011;11:56\u201366. \n                    https:\/\/doi.org\/10.1102\/1470-7330.2011.0012\n                    \n                  .","journal-title":"Cancer Imaging"},{"issue":"1","key":"224_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2967\/jnumed.117.193706","volume":"59","author":"H Hanscheid","year":"2018","unstructured":"Hanscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose mapping after endoradiotherapy with 177Lu-DOTATATE\/DOTATOC by a single measurement after 4 days. J Nucl Med. 2018;59(1):75\u201381. \n                    https:\/\/doi.org\/10.2967\/jnumed.117.193706\n                    \n                  .","journal-title":"J Nucl Med"},{"issue":"9","key":"224_CR9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"Suppl. 1","key":"224_CR10","first-page":"242","volume":"58","author":"M Del Prete","year":"2017","unstructured":"Del Prete M, Buteau FA, Beaulieu A, Beauregard JM. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumors: initial dosimetry and safety results of the P-PRRT trial. J Nucl Med. 2017;58(Suppl. 1):242.","journal-title":"J Nucl Med"},{"issue":"1","key":"224_CR11","first-page":"37","volume":"54","author":"M Cremonesi","year":"2010","unstructured":"Cremonesi M, Botta F, Di Dia A, Ferrari M, Bodei L, De Cicco C, et al. Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q J Nucl Med Mol Imaging. 2010;54(1):37\u201351.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"224_CR12","doi-asserted-by":"publisher","unstructured":"Svensson J, Ryd\u00e9n T, Hagmarker L, Hemmingsson J, W\u00e4ngberg B, Bernhardt P. A novel planar image-based method for bone marrow dosimetry in 177Lu-DOTATATE treatment correlates with haematological toxicity. EJNMMI Physics. 2016;3:21. \n                    https:\/\/doi.org\/10.1186\/s40658-016-0157-0\n                    \n                  .","DOI":"10.1186\/s40658-016-0157-0"},{"key":"224_CR13","doi-asserted-by":"publisher","unstructured":"Hagmarker L, Svensson J, Ryd\u00e9n T, Gjertsson P, Bernhardt P. Segmentation of whole-body images into two compartments in model for bone marrow dosimetry increases the correlation with hematological response in 177Lu-DOTATATE treatments. Cancer Biother Radiopharm. 2017;32(9):335\u201343. \n                    https:\/\/doi.org\/10.1089\/cbr.2017.2317\n                    \n                  .","DOI":"10.1089\/cbr.2017.2317"},{"issue":"1","key":"224_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40658-016-0170-3","volume":"4","author":"CF Uribe","year":"2017","unstructured":"Uribe CF, Esquinas PL, Tanguay J, Gonzalez M, Gaudin E, Beauregard JM, et al. Accuracy of 177Lu activity quantification in SPECT imaging: a phantom study. EJNMMI Phys. 2017;4(1):2. \n                    https:\/\/doi.org\/10.1186\/s40658-016-0170-3\n                    \n                  .","journal-title":"EJNMMI Phys"},{"issue":"2","key":"224_CR15","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s00259-009-1216-8","volume":"37","author":"M Sandstrom","year":"2010","unstructured":"Sandstrom M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate. Eur J Nucl Med Mol Imaging. 2010;37(2):212\u201325. \n                    https:\/\/doi.org\/10.1007\/s00259-009-1216-8\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"224_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s00259-010-1549-3","volume":"38","author":"M Lassmann","year":"2011","unstructured":"Lassmann M, Chiesa C, Flux G, Bardies M, Committee ED. EANM dosimetry committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging. 2011;38(1):192\u2013200. \n                    https:\/\/doi.org\/10.1007\/s00259-010-1549-3\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"224_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40658-015-0127-y","volume":"2","author":"M Sandstrom","year":"2015","unstructured":"Sandstrom M, Ilan E, Karlberg A, Johansson S, Freedman N, Garske-Roman U. Method dependence, observer variability and kidney volumes in radiation dosimetry of 177Lu-DOTATATE therapy in patients with neuroendocrine tumours. EJNMMI Phys. 2015;2(1):24. \n                    https:\/\/doi.org\/10.1186\/s40658-015-0127-y\n                    \n                  .","journal-title":"EJNMMI Phys"},{"issue":"1","key":"224_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00259-011-1937-3","volume":"39","author":"JM Beauregard","year":"2012","unstructured":"Beauregard JM, Hofman MS, Kong G, Hicks RJ. The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39(1):50\u20136. \n                    https:\/\/doi.org\/10.1007\/s00259-011-1937-3\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["EJNMMI Physics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40658-018-0224-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40658-018-0224-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40658-018-0224-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T19:04:19Z","timestamp":1571079859000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmiphys.springeropen.com\/articles\/10.1186\/s40658-018-0224-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,15]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["224"],"URL":"https:\/\/doi.org\/10.1186\/s40658-018-0224-9","relation":{},"ISSN":["2197-7364"],"issn-type":[{"value":"2197-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,15]]},"assertion":[{"value":"4 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Specifically, for the 23 patients who received only empiric PRRT until March 2016, the requirement for consent was waived due to the retrospective nature of the analysis. All other patients were enrolled in our P-PRRT trial (NCT02754297) and gave informed consent to participate.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read the manuscript and consented for its publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"25"}}